Ex­clu­sive: Dupix­ent in a pill? Start­up In­samo will try to turn block­buster bi­o­log­ics in­to orals

A new biotech start­up launched Wednes­day to ad­vance a “Goldilocks” ther­a­peu­tic modal­i­ty that could turn some of the in­dus­try’s most lu­cra­tive drugs in­to pills.

Berke­ley, CA-head­quar­tered In­samo was found­ed in 2022 by a trio of PhD sci­en­tists, who have raised a $12 mil­lion seed round that in­cludes in­vestors like ven­Bio and Play­ground Glob­al, CEO Tim Craven told End­points News ex­clu­sive­ly. The board in­cludes Play­ground’s ven­ture part­ner Matt Her­shen­son and is chaired by ven­Bio man­ag­ing part­ner Corey Good­man.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER